The following transcript has been edited for clarity.

Hi, I’m Carl C. Awh, MD, FASRS. I’m a retina specialist with Tennessee Retina in Nashville. I just presented late-breaking results of 4D-150, a gene therapy from 4DMT for neovascular age-related macular degeneration (nAMD).

What we presented were 2-year outcomes of patients in a subgroup of patients in the phase 2b study. So these were patients with relatively recently diagnosed disease. What we found is outcomes similar to what’s been shown in the larger phase 2 study, but actually even better. We found that in this more recently diagnosed subgroup of patients, 66% of patients went 2 years without any additional injections. Eighty-seven percent had far fewer injections than would've been done with standard-of-care aflibercept (Eylea; Regeneron). So the overwhelming majority of patients had 2 or fewer injections over 2 years with outstanding maintenance of vision and great optical coherence tomography (OCT) outcomes.

What was particularly encouraging is that these excellent results were achieved with apparent great safety. There were 2 eyes that had minimal iritis during the first 28 weeks of the study. This was treated with topical therapy. For up to 4 years of follow-up, no other eyes in any arm of the phase 2 study has had any other inflammation or any other serious adverse event. So this combination of safety and durability is compelling.

We know that the major threat to our patients’ vision with nAMD is undertreatment. The treatment burden of injections of drugs that are very effective, but that have to be given at really specific intervals for so many of our patients—that’s just a very impossible burden we've seen in every country to achieve. So having something that will free us from that burden of injections is tremendously valuable to patients, to doctors, and to patients’ families. So we’re very happy to present that information and look forward to the phase 3 results that will come out in 2027. RP